Researchers at the Feinstein Institutes for Medical Research have developed a groundbreaking new method for vagus nerve stimulation (VNS) that offers unprecedented control over nerve fiber activation, paving the way for more effective and personalized treatments for a wide range of chronic diseases.
Obesity affects over a third of the global population and is a major risk factor for numerous chronic diseases. To find better therapies to fight obesity and its related health problems, researchers at Northwell Health’s Feinstein Institutes for Medical Research are investigating a promising new approach in which vagus nerve stimulation (VNS) interacts with growth factor-β (TGF-β) signaling, a driver and suppressor of metabolic function.
Piramal Pharma Limited a leading global pharmaceuticals and wellness company, in conjunction with the 2025 SelectUSA Investment Summit, commits to a $90M investment plan towards expanding two of the Company's US facilities. These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation.
SFI Health™ is proud to celebrate the 25th anniversary of Equazen®, a globally recognized, science-based food supplement designed to nourish, enhance, and support the brain's potential. Since its market debut in 2000, Equazen® has remained committed to innovation and pharma-quality standards, establishing itself as a leading brand in cognitive health supplements.
Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, is highlighting its latest advancements in digital orthopaedics at the American Academy of Orthopaedic
CollPlant Biotechnologies , or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update.
BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study. The findings highlight the transformative potential of its ProsperaTM Spinal Cord Stimulation (SCS) system.
Zymo Research is proud to introduce the Master the Microbiome Grant, a global initiative dedicated to advancing research in microbiomics, metagenomics, and microbial sciences. This grant empowers researchers by providing access to industry-leading sample and library preparation solutions and services, as well as opportunities to share their research with the field at-large.
A team of international researchers led by scientists at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation’s top 5 cancer centers by U.S. News & World Report, have demonstrated a way to boost thymic function after damage in preclinical studies.
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a Concept Stage winner of the United States Biomedical Advanced Research and Development Authority’s (BARDA’s) $50 million Patch Forward Prize.